GSK J4 is a cell permeable prodrug rapidly hydrolyzed by macrophage esterases to GSK-J1, a potent selective jumonji H3K27 demethylase inhibitor and attenuates lipopolysaccharide (LPS)-induced proinflammatory cytokine production in primary human macrophages (IC50 = 9 μM for the inhibition of TNFα release).
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | KDM1 ↓ ↑ | KDM2 ↓ ↑ | KDM3 ↓ ↑ | KDM4 ↓ ↑ | KDM5 ↓ ↑ | KDM6 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OG-L002 |
+++
LSD1, IC50: 20 nM |
99%+ | |||||||||||||||||
ORY-1001 |
+++
LSD1, IC50: 20 nM |
98% | |||||||||||||||||
SP-2509 |
++++
LSD1, IC50: 13 nM |
98+% | |||||||||||||||||
GSK2879552 2HCl |
+
LSD1, Ki: 1.7 μM |
99%+ | |||||||||||||||||
T-3775440 HCl |
++++
LSD1, IC50: 2.1 nM |
99% | |||||||||||||||||
GSK-LSD1 2HCl |
+++
LSD1, IC50: 16 nM |
98% | |||||||||||||||||
Pulrodemstat benzenesulfonate | ✔ | 99%+ | |||||||||||||||||
IOX1 |
+
KDM2A, IC50: 1.8 μM |
+++
KDM3A, IC50: 0.1 μM |
++
KDM4E, IC50: 2.3 μM KDM4C, IC50: 0.6 μM |
+
KDM5C, IC50: 19 μM |
+
KDM6B, IC50: 1.6 μM |
99% | |||||||||||||
PFI-90 | ✔ | 99%+ | |||||||||||||||||
ML324 |
+
JMJD2, IC50: 920 nM |
99%+ | |||||||||||||||||
(Z)-JIB-04 |
++
JMJD2A, IC50: 1100 nM JMJD2E, IC50: 340 nM |
++
JARID1A, IC50: 230 nM |
++
JMJD3, IC50: 855 nM |
97% | |||||||||||||||
JIB-04 |
++
JMJD2D, IC50: 290 nM JMJD2E, IC50: 435 nM |
++
JARID1A, IC50: 230 nM |
++
JMJD3, IC50: 855 nM |
98% | |||||||||||||||
NCGC00244536 |
++++
KDM4, IC50: 10 nM |
99% | |||||||||||||||||
KDM4D-IN-1 |
++
KDM4D, IC50: 0.41 μM |
99%+ | |||||||||||||||||
GSK467 |
++++
KDM5B, Ki: 10 nM |
99% | |||||||||||||||||
GSK-J1 |
+++
JMJD3, IC50: 60 nM |
99%+ | |||||||||||||||||
CPI-455 |
++++
KDM5A, IC50: 10 nM |
++++
KDM5, IC50: 10 nM |
98% | ||||||||||||||||
GSK-J4 HCl |
+++
JMJD3, IC50: 60 nM |
98% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | GSK-J4, acting as a robust dual inhibitor of the demethylases JMJD3/KDM6B and UTX/KDM6A with IC50 values of 8.6 μM and 6.6 μM respectively, curbs LPS-induced TNF-α output in human primary macrophages with an IC50 of 9 μM. It effectively maintains H3K27me3 levels in the nucleus, notably reducing the expression of multiple LPS-driven cytokines, including TNF-α. |
Animal study | GSK-J4 Hydrochloride administered intraperitoneally at 10 mg/kg three times weekly for 10 weeks lessens the progression of kidney disease in diabetic mice[2].GSK-J4, given intraperitoneally at 0.5 mg/kg, significantly mitigates the severity and postpones the onset of experimental autoimmune encephalomyelitis in a mouse model[3]. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.40mL 0.48mL 0.24mL |
11.98mL 2.40mL 1.20mL |
23.95mL 4.79mL 2.40mL |
CAS号 | 1373423-53-0 |
分子式 | C24H27N5O2 |
分子量 | 417.5 |
SMILES Code | O=C(OCC)CCNC1=NC(C2=NC=CC=C2)=NC(N3CCC4=CC=CC=C4CC3)=C1 |
MDL No. | MFCD22683852 |
别名 | |
运输 | 蓝冰 |
InChI Key | WBKCKEHGXNWYMO-UHFFFAOYSA-N |
Pubchem ID | 71729975 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Inert atmosphere, 2-8°C |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|